These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
678 related articles for article (PubMed ID: 12659402)
1. Yasmin: the reason why. Thorneycroft IH Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402 [TBL] [Abstract][Full Text] [Related]
2. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives]. Cianci A; De Leo V Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832 [TBL] [Abstract][Full Text] [Related]
3. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Oelkers W Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403 [TBL] [Abstract][Full Text] [Related]
4. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Boschitsch E; Skarabis H; Wuttke W; Heithecker R Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600 [TBL] [Abstract][Full Text] [Related]
5. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being. Mansour D Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405 [TBL] [Abstract][Full Text] [Related]
6. Added benefits of drospirenone for compliance. Foidart JM Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653 [TBL] [Abstract][Full Text] [Related]
7. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. Freeman EW Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404 [TBL] [Abstract][Full Text] [Related]
9. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Oelkers W Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598 [TBL] [Abstract][Full Text] [Related]
10. Yasmin--a new oral contraceptive, a new progestogen: the reasons why. Mansour D Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():9-16. PubMed ID: 11246601 [TBL] [Abstract][Full Text] [Related]
11. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Foidart JM Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599 [TBL] [Abstract][Full Text] [Related]
12. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400 [TBL] [Abstract][Full Text] [Related]
13. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629 [TBL] [Abstract][Full Text] [Related]
14. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Oelkers WH Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652 [TBL] [Abstract][Full Text] [Related]
15. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825 [TBL] [Abstract][Full Text] [Related]
16. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282 [TBL] [Abstract][Full Text] [Related]
17. Psychosexual well-being in women using oral contraceptives containing drospirenone. Nappi RE; Albani F; Tonani S; Santamaria V; Pisani C; Terreno E; Martini E; Polatti F Funct Neurol; 2009; 24(2):71-5. PubMed ID: 19775533 [TBL] [Abstract][Full Text] [Related]
18. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes. Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838 [TBL] [Abstract][Full Text] [Related]
19. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162 [TBL] [Abstract][Full Text] [Related]
20. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Keam SJ; Wagstaff AJ Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]